Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 160

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 160
---
 with reimbursement consultants to develop potential Category I CPT codes for Lumee Oxygen use.

Regarding Lumee Glucose, if
and when we obtained marketing authorization, we plan to embark on a dual strategy of both direct to hospital sales, for our professional-use
and personal-use CGM product, and direct to pharmacy sales for our personal use product only, thereby maximizing flexibility for the consumer.
By aiming for coverage under a user’s pharmacy benefit, we believe we can diversify our user base, while accounting for any risk
related to unlikely delay of attainment of a category I CPT code for sensor insertion. We feel a difference between other insertable
or implantable CGMs and Lumee Glucose, is that the latter can be simply inserted with a hypodermic needle and does not require a surgical
implantation, similar to how pharmacists use these needles to administer flu shots and other vaccines. At the same time, physicians can
still leverage existing CPT codes related to interpretation of CGM data and we have, in parallel, initiated steps for CPT codes related
to our sensor insertion. We will target both public and private payors for coverage.

<div align='center'>91</div>

Since our launch, we have significantly
devoted all of our resources to research and development, as well as all clinical study activities related but not limited to Lumee Oxygen,
Lumee Glucose and prototypes for sensors of at least eight other analytes. We have also invested, on a smaller scale, in making sales
of Lumee Oxygen for research- use only clients, which include entities working with animal models. Furthermore, we also performed research
and development under government grants.

Since inception, we have incurred
recurring annual losses from operations. For the three months ended June 30, 2025 and 2024, we incurred a net loss of $2.3 million
and $2.0 million, respectively. For the six months ended June 30, 2025 and 2024, we incurred a net loss of $5.1 million
and $4.5 million, respectively. During the six months ended June 30, 2025 and 2024, we have used $1.1 million and
$1.0 million, respectively, of cash in our operating activities. We have notes and loans payable and interest due of $52.3 million
within twelve months of June 30, 2025.

We have been able to finance
our